High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

Lenalidomide – Current Understanding of Mechanistic Properties

(2012) Nishant Tageja   Anti-Cancer Agents in Medicinal Chemistry

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

(2011) Antonia Lopez-Girona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Teratogenic effects of thalidomide: molecular mechanisms

(2011) Takumi Ito et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Pomalidomide therapy for myeloma

(2011) Stephen Schey et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

New Immunomodulatory Drugs in Myeloma

(2011) Martha Q. Lacy   Current Hematologic Malignancy Reports

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

IRF4: Immunity. Malignancy! Therapy?

(2009) A. L. Shaffer et al.   CLINICAL CANCER RESEARCH

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

First thalidomide clinical trial in multiple myeloma: a decade

(2008) F. van Rhee et al.   BLOOD

Lenalidomide: a novel anticancer drug with multiple modalities

(2008) Christine Galustian et al.   EXPERT OPINION ON PHARMACOTHERAPY

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

(2008) Sonia Vallet et al.   LEUKEMIA & LYMPHOMA

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE